^
    Back
    Association details:
    Biomarker:FLT3 Y842C
    Cancer:Acute Myelogenous Leukemia
    Drug:Vanflyta (quizartinib) (FLT3 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Nature
    Title:

    Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

    Excerpt:
    The five substitutions that conferred a high degree of resistance to AC220 in vitro were cross-resistant to sorafenib in cell-based growth and biochemical assays (Supplementary Fig. 4). The degree of relative resistance to sorafenib associated with these mutants was generally similar to that observed with AC220.
    DOI:
    https://dx.doi.org/10.1038%2Fnature11016
    Trial ID:
    NCT00989261
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Clin Cancer Res
    Title:

    Reversal of Acquired Drug Resistance in FLT3-mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies

    Excerpt:
    AC220 demonstrated a similar pattern of resistance as observed with sorafenib treatment (Fig. 2A).
    DOI:
    https://dx.doi.org/10.1158%2F1078-0432.CCR-13-2052